Heparin Induced Thrombocytopenia: Pharmacoeconomics
Patients at BWH receiving unfractionated heparin or enoxaparin who subsequently develop heparin induced thrombocytopenia will be identified via a computer generated report designed for the purposes of this study.
Subsequently, we will compare the heparin induced thrombocytopenia rates associated with heparin and low molecular weight heparin usage as well as evaluate the economic and long-term clinical burden of heparin induced thrombocytopenia.
Heparin Induced Thrombocytopenia (HIT)
|Study Design:||Observational Model: Cohort
Time Perspective: Retrospective
|Official Title:||Study to Compare the Heparin Induced Thrombocytopenia Rates Associated With Heparin and Low Molecular Weight Heparin Usage as Well as Evaluate the Economic and Long-Term Clinical Burden of Heparin Induced Thrombocytopenia.|
- Clotting and Bleeding Complications [ Time Frame: 90 Days ] [ Designated as safety issue: No ]
- Mortality [ Time Frame: 30 Days ] [ Designated as safety issue: No ]
|Study Start Date:||July 2006|
|Study Completion Date:||January 2009|
|Primary Completion Date:||September 2008 (Final data collection date for primary outcome measure)|
|United States, Massachusetts|
|Brigham and Women's Hospital|
|Boston, Massachusetts, United States, 02115|
|Principal Investigator:||Samuel Z. Goldhaber, MD||Brigham and Women's Hospital|